Douglas J. Goetz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Douglas J. Goetz has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Davoud Ghazanfari
Department of Chemical and Biomolecular Engineering, Ohio University, Athens, USA
5 shared publicationsKelly D. McCall
Department of Specialty Medicine, Ohio University, Athens, USA
5 shared publicationsStephen C. Bergmeier
Biomedical Engineering Program, Ohio University, Athens, USA
5 shared publicationsMahboubeh S. Noori
Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH 45701, United States
4 shared publicationsSudhir P. Deosarkar
Interthyr Corporation, Marietta, Ohio
3 shared publicationsVivek R. Shinde Patil
3 shared publications
Latest Publications
- Open Access
- 16 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10
During a SARS-CoV-2 infection, macrophages recognize viral components resulting in cytokine production. While this response fuels virus elimination, overexpression of cytokines can lead to severe COVID-19. Previous studies suggest that the spike protein (S) of SARS-CoV-2 can elicit cytokine production via the transcription factor NF-κB and the toll-like receptors (TLRs). In this study, we found that: (i) S and the S2 subunit induce CXCL10, a chemokine implicated in severe COVID-19, gene expression by human macrophage cells (THP-1); (ii) a glycogen synthase kinase-3 inhibitor attenuates this induction; (iii) S and S2 do not activate NF-κB but do activate the transcription factor IRF; (iv) S and S2 do not require TLR2 to elicit CXCL10 production or activate IRF; and (v) S and S2 elicit CXCL10 production by peripheral blood mononuclear cells (PBMCs). We also discovered that the cellular response, or lack thereof, to S and S2 is a function of the recombinant S and S2 used. While such a finding raises the possibility of confounding LPS contamination, we offer evidence that potential contaminating LPS does not underly induced increases in CXCL10. Combined, these results provide insights into the complex immune response to SARS-CoV-2 and suggest possible therapeutic targets for severe COVID-19.
- 16 May 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessMechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10
During a SARS-CoV-2 infection, macrophages recognize viral components resulting in cytokine production. While this response fuels virus elimination, overexpression of cytokines can lead to severe COVID-19. Previous studies suggest that the spike protein (S) of SARS-CoV-2 can elicit cytokine production via the transcription factor NF-κB and the toll-like receptors (TLRs). In this study, we found that: (i) S and the S2 subunit induce CXCL10, a chemokine implicated in severe COVID-19, gene expression by human macrophage cells (THP-1); (ii) a glycogen synthase kinase-3 inhibitor attenuates this induction; (iii) S and S2 do not activate NF-κB but do activate the transcription factor IRF; (iv) S and S2 do not require TLR2 to elicit CXCL10 production or activate IRF; and (v) S and S2 elicit CXCL10 production by peripheral blood mononuclear cells (PBMCs). We also discovered that the cellular response, or lack thereof, to S and S2 is a function of the recombinant S and S2 used. While such a finding raises the possibility of confounding LPS contamination, we offer evidence that potential contaminating LPS does not underly induced increases in CXCL10. Combined, these results provide insights into the complex immune response to SARS-CoV-2 and suggest possible therapeutic targets for severe COVID-19.
- 16 March 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 605, 171-176
Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19
- 16 March 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 605, 171-176
Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19
- 27 April 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 40, 116179
A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism
- 27 April 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 40, 116179
A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism
- 21 October 2020
- Published by Elsevier in Leukemia Research
- Vol. 99, 106464
Evidence that knock down of GSK-3β in Chronic Myelogenous Leukemia cells augments IFN-γ-induced apoptosis
- 21 October 2020
- Published by Elsevier in Leukemia Research
- Vol. 99, 106464
Evidence that knock down of GSK-3β in Chronic Myelogenous Leukemia cells augments IFN-γ-induced apoptosis
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 883, 173340
Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 883, 173340
Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor
- 21 January 2020
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 13 (2) , 113-124
Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging
Cancers of the digestive tract cause nearly one quarter of the cancer deaths worldwide, and nearly half of these are due to cancers of the esophagus and colon. Early detection of cancer significantly increases the rate of survival, and thus it is critical that cancer within these organs is detected early. In this regard, endoscopy is routinely used to screen for transforming/cancerous (i.e. dysplastic to fully cancerous) tissue. Numerous studies have revealed that the biochemistry of the luminal surface of such tissue within the colon and esophagus becomes altered throughout disease progression. Molecular endoscopic imaging (MEI), an emerging technology, seeks to exploit these changes for the early detection of cancer. The general approach for MEI is as follows: the luminal surface of an organ is exposed to molecular ligands, or particulate probes bearing a ligand, cognate to biochemistry unique to pre-cancerous/cancerous tissue. After a wash, the tissue is imaged to determine the presence of the probes. Detection of the probes post-washing suggests pathologic tissue. In the current review we provide a succinct, but extensive, review of ligands and target moieties that could be, or are currently being investigated, as possible cognate chemistries for MEI. This is followed by a review of the biophysics that determines, in large part, the success of a particular MEI design. The work draws an analogy between MEI and the well-advanced field of cell adhesion and provides a road map for engineering MEI to achieve assays that yield highly selective recognition of transforming/cancerous tissue in situ.
- 21 January 2020
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 13 (2) , 113-124
Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging
Cancers of the digestive tract cause nearly one quarter of the cancer deaths worldwide, and nearly half of these are due to cancers of the esophagus and colon. Early detection of cancer significantly increases the rate of survival, and thus it is critical that cancer within these organs is detected early. In this regard, endoscopy is routinely used to screen for transforming/cancerous (i.e. dysplastic to fully cancerous) tissue. Numerous studies have revealed that the biochemistry of the luminal surface of such tissue within the colon and esophagus becomes altered throughout disease progression. Molecular endoscopic imaging (MEI), an emerging technology, seeks to exploit these changes for the early detection of cancer. The general approach for MEI is as follows: the luminal surface of an organ is exposed to molecular ligands, or particulate probes bearing a ligand, cognate to biochemistry unique to pre-cancerous/cancerous tissue. After a wash, the tissue is imaged to determine the presence of the probes. Detection of the probes post-washing suggests pathologic tissue. In the current review we provide a succinct, but extensive, review of ligands and target moieties that could be, or are currently being investigated, as possible cognate chemistries for MEI. This is followed by a review of the biophysics that determines, in large part, the success of a particular MEI design. The work draws an analogy between MEI and the well-advanced field of cell adhesion and provides a road map for engineering MEI to achieve assays that yield highly selective recognition of transforming/cancerous tissue in situ.
- 25 September 2019
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 317 (6) , C1289-C1303
Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3
Glycogen synthase kinase-3 (GSK-3) is a multitasking protein kinase that regulates numerous critical cellular functions. Not surprisingly, elevated GSK-3 activity has been implicated in a host of diseases including pathological inflammation, diabetes, cancer, arthritis, asthma, bipolar disorder, and Alzheimer’s. Therefore, reagents that inhibit GSK-3 activity provide a means to investigate the role of GSK-3 in cellular physiology and pathophysiology and could become valuable therapeutics. Finding a potent inhibitor of GSK-3 that can selectively target this kinase, among over 500 protein kinases in the human genome, is a significant challenge. Thus there remains a critical need for the identification of selective inhibitors of GSK-3. In this work, we introduce a novel small organic compound, namely COB-187, which exhibits potent and highly selective inhibition of GSK-3. Specifically, this study 1) utilized a molecular screen of 414 kinase assays, representing 404 unique kinases, to reveal that COB-187 is a highly potent and selective inhibitor of GSK-3; 2) utilized a cellular assay to reveal that COB-187 decreases the phosphorylation of canonical GSK-3 substrates indicating that COB-187 inhibits cellular GSK-3 activity; and 3) reveals that a close isomer of COB-187 is also a selective and potent inhibitor of GSK-3. Taken together, these results demonstrate that we have discovered a region of chemical design space that contains novel GSK-3 inhibitors. These inhibitors will help to elucidate the intricate function of GSK-3 and can serve as a starting point for the development of potential therapeutics for diseases that involve aberrant GSK-3 activity.
- 25 September 2019
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 317 (6) , C1289-C1303
Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3
Glycogen synthase kinase-3 (GSK-3) is a multitasking protein kinase that regulates numerous critical cellular functions. Not surprisingly, elevated GSK-3 activity has been implicated in a host of diseases including pathological inflammation, diabetes, cancer, arthritis, asthma, bipolar disorder, and Alzheimer’s. Therefore, reagents that inhibit GSK-3 activity provide a means to investigate the role of GSK-3 in cellular physiology and pathophysiology and could become valuable therapeutics. Finding a potent inhibitor of GSK-3 that can selectively target this kinase, among over 500 protein kinases in the human genome, is a significant challenge. Thus there remains a critical need for the identification of selective inhibitors of GSK-3. In this work, we introduce a novel small organic compound, namely COB-187, which exhibits potent and highly selective inhibition of GSK-3. Specifically, this study 1) utilized a molecular screen of 414 kinase assays, representing 404 unique kinases, to reveal that COB-187 is a highly potent and selective inhibitor of GSK-3; 2) utilized a cellular assay to reveal that COB-187 decreases the phosphorylation of canonical GSK-3 substrates indicating that COB-187 inhibits cellular GSK-3 activity; and 3) reveals that a close isomer of COB-187 is also a selective and potent inhibitor of GSK-3. Taken together, these results demonstrate that we have discovered a region of chemical design space that contains novel GSK-3 inhibitors. These inhibitors will help to elucidate the intricate function of GSK-3 and can serve as a starting point for the development of potential therapeutics for diseases that involve aberrant GSK-3 activity.
- 19 December 2018
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 10 (12) , 747-757
An adhesion based approach for the detection of esophageal cancer
Selective recognition of esophageal cancer cellsvialigand conjugated microspheres in an endoscopic adhesion assay.
- 19 December 2018
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 10 (12) , 747-757
An adhesion based approach for the detection of esophageal cancer
Selective recognition of esophageal cancer cellsvialigand conjugated microspheres in an endoscopic adhesion assay.
- 28 July 2011
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 39 (10) , 2627-2636
A Quantitative Real-Time PCR Approach for the Detection and Characterization of Endothelial Cells in Whole Blood
Pathological inflammation and endothelial dysfunction in atherosclerosis causes endothelial cell detachment from affected vasculature giving rise to circulating endothelial cells (CECs). A blood-based assay that can detect and characterize CECs in atherosclerosis could serve as a valuable diagnostic. Thus, we sought to develop a prototypic assay that detects and characterizes the inflammatory state of endothelial cells present in blood. For this purpose, we spiked resting and inflamed human umbilical vein endothelial cells (HUVEC) into separate samples of whole blood. RNA was harvested and analyzed via quantitative real-time PCR (qPCR) using melanoma cell adhesion molecule (MCAM), as an endothelial marker, and vascular cell adhesion molecule (VCAM-1), which is increased on inflamed endothelium. We found that MCAM mRNA levels correlated with the number of HUVEC spiked into the blood. VCAM-1 mRNA levels were elevated, and correlated with the number of HUVEC, in blood spiked with inflamed HUVEC but not in blood spiked with resting HUVEC. VCAM-1 and MCAM mRNA levels were converted into numerical indices that indicate the inflammatory state of the HUVEC. Combined, the blood spiking studies demonstrate that a VCAM-1/MCAM qPCR assay can successfully detect inflamed endothelial cells in whole blood thus providing proof-of-concept for a diagnostic based on a coupled-phenotypic qPCR assay.
- 28 July 2011
- Published by Springer Nature in Annals of Biomedical Engineering
- Vol. 39 (10) , 2627-2636
A Quantitative Real-Time PCR Approach for the Detection and Characterization of Endothelial Cells in Whole Blood
Pathological inflammation and endothelial dysfunction in atherosclerosis causes endothelial cell detachment from affected vasculature giving rise to circulating endothelial cells (CECs). A blood-based assay that can detect and characterize CECs in atherosclerosis could serve as a valuable diagnostic. Thus, we sought to develop a prototypic assay that detects and characterizes the inflammatory state of endothelial cells present in blood. For this purpose, we spiked resting and inflamed human umbilical vein endothelial cells (HUVEC) into separate samples of whole blood. RNA was harvested and analyzed via quantitative real-time PCR (qPCR) using melanoma cell adhesion molecule (MCAM), as an endothelial marker, and vascular cell adhesion molecule (VCAM-1), which is increased on inflamed endothelium. We found that MCAM mRNA levels correlated with the number of HUVEC spiked into the blood. VCAM-1 mRNA levels were elevated, and correlated with the number of HUVEC, in blood spiked with inflamed HUVEC but not in blood spiked with resting HUVEC. VCAM-1 and MCAM mRNA levels were converted into numerical indices that indicate the inflammatory state of the HUVEC. Combined, the blood spiking studies demonstrate that a VCAM-1/MCAM qPCR assay can successfully detect inflamed endothelial cells in whole blood thus providing proof-of-concept for a diagnostic based on a coupled-phenotypic qPCR assay.
- 12 March 2008
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 101 (2) , 400-407
Polymeric particles conjugated with a ligand to VCAM‐1 exhibit selective, avid, and focal adhesion to sites of atherosclerosis
The increased expression of VCAM‐1 on endothelial segments within plaque regions could be used as a target to deliver polymeric drug carriers selectively to sites of atherosclerosis. We probed the hypothesis that polymeric particles conjugated with a ligand for VCAM‐1 exhibit selective and avid adhesion to sites of atherosclerosis. Particles made from polystyrene or the biodegradable polymer poly(sebacic acid)‐block‐polyethylene glycol (PSA‐PEG) were conjugated with an antibody to VCAM‐1 (α‐VCAM‐1) or IgG (negative control). The particles were injected into the jugular vein of ApoE−/− (a murine model of atherosclerosis) or wild type mice and their adhesion to the aorta determined. α‐VCAM‐1 particles exhibited significantly greater adhesion to ApoE−/− mouse aorta [32 ± 5 (mean ± SEM) particles/mm2 for polystyrene particles and 31 ± 7 particles/mm2 for PSA‐PEG particles] compared to the level of adhesion to wild type mouse aorta (18 ± 1 particles/mm2 for polystyrene particles and 6 ± 1 particles/mm2 for PSA‐PEG particles). Within ApoE−/− mice, the α‐VCAM‐1 particles exhibited significantly greater adhesion to the aorta (32 ± 5 particles/mm2 for polystyrene particles and 31 ± 7 particles/mm2 for PSA‐PEG particles) compared to the adhesion of IgG particles (1 ± 1 particles/mm2 for polystyrene particles and 2 ± 1 particles/mm2 for PSA‐PEG particles). Detailed analysis of the adhesion revealed that α‐VCAM‐1 particles exhibited focal adhesion to plaque regions, in particular the periphery of the plaques, within the ApoE−/− mouse aorta. Combined the data demonstrate that polymeric particles conjugated with a ligand to VCAM‐1 exhibit selective, avid and focal adhesion to sites of atherosclerosis providing strong evidence that VCAM‐1 ligand bearing polymeric particles could be used for targeting drugs selectively to atherosclerotic tissue. Biotechnol. Bioeng. 2008;101: 400–407.
- 12 March 2008
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 101 (2) , 400-407
Polymeric particles conjugated with a ligand to VCAM‐1 exhibit selective, avid, and focal adhesion to sites of atherosclerosis
The increased expression of VCAM‐1 on endothelial segments within plaque regions could be used as a target to deliver polymeric drug carriers selectively to sites of atherosclerosis. We probed the hypothesis that polymeric particles conjugated with a ligand for VCAM‐1 exhibit selective and avid adhesion to sites of atherosclerosis. Particles made from polystyrene or the biodegradable polymer poly(sebacic acid)‐block‐polyethylene glycol (PSA‐PEG) were conjugated with an antibody to VCAM‐1 (α‐VCAM‐1) or IgG (negative control). The particles were injected into the jugular vein of ApoE−/− (a murine model of atherosclerosis) or wild type mice and their adhesion to the aorta determined. α‐VCAM‐1 particles exhibited significantly greater adhesion to ApoE−/− mouse aorta [32 ± 5 (mean ± SEM) particles/mm2 for polystyrene particles and 31 ± 7 particles/mm2 for PSA‐PEG particles] compared to the level of adhesion to wild type mouse aorta (18 ± 1 particles/mm2 for polystyrene particles and 6 ± 1 particles/mm2 for PSA‐PEG particles). Within ApoE−/− mice, the α‐VCAM‐1 particles exhibited significantly greater adhesion to the aorta (32 ± 5 particles/mm2 for polystyrene particles and 31 ± 7 particles/mm2 for PSA‐PEG particles) compared to the adhesion of IgG particles (1 ± 1 particles/mm2 for polystyrene particles and 2 ± 1 particles/mm2 for PSA‐PEG particles). Detailed analysis of the adhesion revealed that α‐VCAM‐1 particles exhibited focal adhesion to plaque regions, in particular the periphery of the plaques, within the ApoE−/− mouse aorta. Combined the data demonstrate that polymeric particles conjugated with a ligand to VCAM‐1 exhibit selective, avid and focal adhesion to sites of atherosclerosis providing strong evidence that VCAM‐1 ligand bearing polymeric particles could be used for targeting drugs selectively to atherosclerotic tissue. Biotechnol. Bioeng. 2008;101: 400–407.